Trial Condition(s):

Vasomotor Symptoms

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

Bayer Identifier:

91354

ClinicalTrials.gov Identifier:

NCT00651599

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.

Inclusion Criteria
- Postmenopausal Korean women suffering from hot flushes
Exclusion Criteria
- Standard exclusion criteria for HRT clinical trials had to be obeyed, including current or history of hormone dependent malignant disease, thromboembolic disorders, abnormal cervical smear, undiagnosed vaginal bleeding.

Trial Summary

Enrollment Goal
90
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
Yes
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Seoul National University Hospital

Seoul, South Korea, 110-744

Status
Completed
 
Locations

Samsung Medical Center

Seoul, South Korea, 135-710

Status
Completed
 
Locations

Inje University Sanggye Paik Hospital

Seoul, South Korea

Status
Completed
 
Locations

Asan Medical Center

Seoul, South Korea, 138-736

Status
Terminated
 
Locations

Chung-Ang University Yongsan Hospital

Seoul, South Korea

Status
Completed
 
Locations

Gangnam Severance Hospital, Yonsei University

Seoul, South Korea

Status
Completed
 

Trial Design